Poxel Secures €5M Equity Line with IRIS to Fund Recovery Plan
Event summary
- Poxel implements a €5M equity line with IRIS Capital, structured as a SmartATM® facility over five years.
- The financing is part of restructuring €4.27M in bond debt held by IRIS, agreed upon in March 2023.
- IRIS may exercise warrants to subscribe up to 40M new shares, representing ~74.41% of Poxel’s current share capital.
- Poxel’s CEO Nicolas Trouche states the recovery plan is now actively underway.
- The equity line includes conditions such as no event of default, material adverse change, or delisting of shares.
The big picture
Poxel’s equity line with IRIS Capital is a strategic move to stabilize its financial footing amid ongoing recovery efforts. The biopharmaceutical company, focused on metabolic diseases like MASH and rare disorders, aims to restructure debt and secure funding without immediate regulatory hurdles. The deal highlights the challenges of balancing liquidity needs with potential dilution risks in a competitive healthcare sector.
What we're watching
- Dilution Impact
- How the issuance of up to 40M new shares will affect existing shareholders' equity and stock price volatility.
- Recovery Plan Execution
- Whether Poxel can successfully implement its recovery plan and meet the conditions for IRIS’s financing.
- Market Reaction
- The pace at which investors respond to the equity line, particularly given IRIS’s intent to sell shares shortly after issuance.
Related topics